DUPIXENT (dupilumab)
ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB · ATOPIC DERMATITIS ·+10
Sanofi-Aventis U.S.
Drug class
Eczema Agents Systemic Interleukin-4 (IL-4Ra)Antag.McAb
Eczema Agents Systemic Interleukin-4 (IL-4Ra)Antag.McAb is an administrative formulary classification used by compendia and health plan prescription lists to categorize systemic biologic therapies targeting the interleukin-4 receptor alpha subunit, primarily represented by dupilumab. Read more about Eczema Agents Systemic Interleukin-4 (IL-4Ra)Antag.McAb
3 drugs in this class 1 manufacturers
Drugs in Eczema Agents Systemic Interleukin-4 (IL-4Ra)Antag.McAb
DUPIXENT PEN (dupilumab)
ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB · ATOPIC DERMATITIS ·+10
Sanofi-Aventis U.S.
DUPIXENT SYRINGE (dupilumab)
ECZEMA AGENTS SYSTEMIC INTERLEUKIN-4 (IL-4RA)ANTAG.MCAB · ATOPIC DERMATITIS ·+10
Sanofi-Aventis U.S.
Filter & compare in the drug finder →
Opens the drug finder with Eczema Agents Systemic Interleukin-4 (IL-4Ra)Antag.McAb preselected. Add indication or manufacturer filters there.
Eczema Agents Systemic Interleukin-4 (IL-4Ra)Antag.McAb is an administrative formulary classification used by compendia and health plan prescription lists to categorize systemic biologic therapies targeting the interleukin-4 receptor alpha subunit, primarily represented by dupilumab.
Agents in this class are human monoclonal antibodies that bind specifically to IL-4Ra, dual-inhibiting downstream signal transduction of both interleukin-4 and interleukin-13 to suppress type 2 inflammatory cascades.
In dermatologic therapeutics, this class is primarily indicated for moderate-to-severe atopic dermatitis that is inadequately controlled with topical therapies, though the mechanism also provides clinical efficacy across other type 2 immune-mediated conditions.
-
communitycarehealth.org
Eczema Agents Systemic Interleukin-4 (IL-4Ra)Antag.McAb is an administrative formulary classification used by compendia and health plan prescription lists to categorize systemic biologic therapies targeting the interleukin-4 receptor alpha subunit, primarily represented by dupilumab Agents in this class are human monoclonal antibodies that bind specifically to IL-4Rα, dual-inhibiting downstream signal transduction of both interleukin-4 and interleukin-13 to suppress type 2 inflammatory cascades ...
-
kaiserpermanente.org
Eczema Agents Systemic Interleukin-4 (IL-4Ra)Antag.McAb is an administrative formulary classification used by compendia and health plan prescription lists to categorize systemic biologic therapies targeting the interleukin-4 receptor alpha subunit, primarily represented by dupilumab
-
berkeley.edu
Eczema Agents Systemic Interleukin-4 (IL-4Ra)Antag.McAb is an administrative formulary classification used by compendia and health plan prescription lists to categorize systemic biologic therapies targeting the interleukin-4 receptor alpha subunit, primarily represented by dupilumab
-
connectrx.com
Agents in this class are human monoclonal antibodies that bind specifically to IL-4Rα, dual-inhibiting downstream signal transduction of both interleukin-4 and interleukin-13 to suppress type 2 inflammatory cascades
-
sfhp.org
In dermatologic therapeutics, this class is primarily indicated for moderate-to-severe atopic dermatitis that is inadequately controlled with topical therapies, though the mechanism also provides clinical efficacy across other type 2 immune-mediated conditions
-
pihhealth.org
In dermatologic therapeutics, this class is primarily indicated for moderate-to-severe atopic dermatitis that is inadequately controlled with topical therapies, though the mechanism also provides clinical efficacy across other type 2 immune-mediated conditions
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.